Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) (“Idera” or the “Company”)
today announced that it intends to offer and sell shares of its common
stock and pre-funded warrants to purchase shares of its common stock in
an underwritten public offering. Piper Jaffray & Co. and Cowen and
Company, LLC are acting as joint bookrunning managers for the offering.
The offering is subject to market conditions, and there can be no
assurance as to whether or when the offering may be completed, or as to
the actual size or terms of the offering.
The securities described above are being offered by the Company pursuant
to a shelf registration statement previously filed with and declared
effective by the Securities and Exchange Commission on September 18,
2013. The offering will be made only by means of the written prospectus
and prospectus supplement that form a part of the registration
statement. Copies of the preliminary prospectus supplement and the
accompanying prospectus relating to the securities being offered may
also be obtained from Piper Jaffray & Co., Attention: Prospectus
Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, via
telephone at 800-747-3924 or email at prospectus@pjc.com;
or from Cowen and Company, LLC, c/o Broadridge Financial Services,
Attention: Prospectus Department, 1155 Long Island Avenue, Edgewood, NY
11717, via telephone at (631) 274-2806 or fax at (631) 254-7140.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy the securities being offered, nor shall
there be any sale of the securities being offered in any state or other
jurisdiction in which such offer, solicitation or sale would be unlawful
prior to the registration or qualification under the securities laws of
any such state or other jurisdiction.
About Idera Pharmaceuticals, Inc.
Idera’s proprietary technology involves creating novel nucleic acid
therapeutics designed to inhibit over-activation of Toll-like Receptors
(TLRs). Idera is developing these therapeutics for the treatment of
genetically defined forms of B-cell lymphoma and for autoimmune diseases
with orphan indications. In addition to its TLR programs, Idera is
developing gene silencing oligonucleotides that it has created using its
proprietary technology, to inhibit the production of disease-associated
proteins by targeting RNA.
Forward Looking Statements
This press release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended, and
Section 21E of the Securities Exchange Act of 1934, as amended. All
statements, other than statements of historical fact, included or
incorporated in this press release, including statements regarding the
Company’s strategy, future operations, collaborations, intellectual
property, cash resources, financial position, future revenues, projected
costs, prospects, plans, and objectives of management, are
forward-looking statements. The words “believes,” “anticipates,”
“estimates,” “plans,” “expects,” “intends,” “may,” “could,” “should,”
“potential,” “likely,” “projects,” “continue,” “will,” and “would” and
similar expressions are intended to identify forward-looking statements,
although not all forward-looking statements contain these identifying
words. Idera cannot guarantee that it will actually achieve the plans,
intentions or expectations disclosed in its forward-looking statements
and you should not place undue reliance on the Company’s forward-looking
statements. There are a number of important factors that could cause
Idera’s actual results to differ materially from those indicated or
implied by its forward-looking statements. Factors that may cause such a
difference include: whether results obtained in early research,
preclinical studies and clinical trials will be indicative of the
results that will be generated in future clinical studies; whether
products based on Idera’s technology will advance into or through the
clinical trial process on a timely basis or at all and receive approval
from the United States Food and Drug Administration or equivalent
foreign regulatory agencies; whether, if the Company’s products receive
approval, they will be successfully distributed and marketed; and such
other important factors as are set forth under the caption “Risk
Factors” in the Company’s Quarterly Report on Form 10-Q for the quarter
ended September 30, 2013. Although Idera may elect to do so at some
point in the future, the Company does not assume any obligation to
update any forward-looking statements and it disclaims any intention or
obligation to update or revise any forward-looking statement, whether as
a result of new information, future events or otherwise.
Copyright Business Wire 2014